


## AMENDMENTS TO THE CLAIMS

Claim 1-7. (Cancelled)

Claim 8. (Previously presented) A veterinary pharmaceutical composition for controlling parasites in or on mammals comprising at least one compound of formula (I)



in which

R<sub>1</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, halo-C<sub>1</sub>-C<sub>6</sub>alkyl, cyano-C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxymethyl or benzyl;

R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> are either, independently of one another, hydrogen, halogen, unsubstituted or mono- or polyhalogenated C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or mono- or polyhalogenated C<sub>2</sub>-C<sub>6</sub>alkenyl, unsubstituted or mono- or polyhalogenated C<sub>2</sub>-C<sub>6</sub>alkynyl; unsubstituted or mono- or polysubstituted C<sub>1</sub>-C<sub>6</sub>alkoxy, unsubstituted or mono- or polysubstituted halo-C<sub>1</sub>-C<sub>6</sub>alkoxy, unsubstituted or mono- or polysubstituted C<sub>3</sub>-C<sub>6</sub>cycloalkyl, in which the substituents in each case can be independent of one another and are chosen from the group consisting of halogen and C<sub>1</sub>-C<sub>6</sub>alkyl; or unsubstituted or mono- or polysubstituted phenyl, in which the substituents can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C<sub>1</sub>-C<sub>6</sub>alkyl, halo-C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, halo-C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkylthio, halo-C<sub>1</sub>-C<sub>6</sub>alkylthio, C<sub>1</sub>-C<sub>6</sub>alkylsulfinyl, halo-C<sub>1</sub>-C<sub>6</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, halo-C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, C<sub>1</sub>-C<sub>6</sub>alkylamino or di-C<sub>1</sub>-C<sub>6</sub>alkylamino;

or R<sub>2</sub> and R<sub>3</sub> are together C<sub>2</sub>-C<sub>6</sub>alkylene;

either

R<sub>7</sub> is unsubstituted or mono- or polysubstituted C<sub>3</sub>-C<sub>6</sub>cycloalkoxy, unsubstituted or mono- or polysubstituted C<sub>3</sub>-C<sub>6</sub>cycloalkylthio, unsubstituted or mono- or polysubstituted (C<sub>3</sub>-C<sub>6</sub>cycloalkyl)(R<sub>9</sub>)N, in which the substituents in each case are chosen from the group consisting of halogen and C<sub>1</sub>-C<sub>6</sub>alkyl; hetaryl or hetarylloxy;

and

R<sub>8</sub> is halogen, nitro, cyano, C<sub>1</sub>-C<sub>6</sub>alkyl, halo-C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, halo-C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>2</sub>-C<sub>6</sub>alkenyl, halo-C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, C<sub>2</sub>-C<sub>6</sub>alkenylloxy, halo-C<sub>2</sub>-C<sub>6</sub>alkenylloxy, C<sub>1</sub>-C<sub>6</sub>alkylthio, halo-C<sub>1</sub>-C<sub>6</sub>alkylthio, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyloxy, halo-C<sub>1</sub>-C<sub>6</sub>alkylsulfonyloxy, C<sub>1</sub>-C<sub>6</sub>alkylsulfinyl, halo-C<sub>1</sub>-C<sub>6</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, halo-C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, C<sub>2</sub>-C<sub>6</sub>alkenylthio, halo-C<sub>2</sub>-C<sub>6</sub>alkenylthio, C<sub>2</sub>-C<sub>6</sub>alkenylsulfinyl, halo-C<sub>2</sub>-C<sub>6</sub>alkenylsulfinyl,

C<sub>2</sub>-C<sub>6</sub>alkenylsulfonyl, halo-C<sub>2</sub>-C<sub>6</sub>alkenylsulfonyl, C<sub>1</sub>-C<sub>6</sub>alkylamino, di-C<sub>1</sub>-C<sub>6</sub>alkylamino, C<sub>1</sub>-C<sub>6</sub>alkylsulfonylamino, halo-C<sub>1</sub>-C<sub>6</sub>alkylsulfonylamino, C<sub>1</sub>-C<sub>6</sub>alkylcarbonyl, halo-C<sub>1</sub>-C<sub>6</sub>alkylcarbonyl, C<sub>1</sub>-C<sub>6</sub>alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>alkylaminocarbonyl, di-C<sub>1</sub>-C<sub>6</sub>alkylaminocarbonyl, unsubstituted or mono- or polysubstituted phenylamino, unsubstituted or mono- or polysubstituted phenylcarbonyl; unsubstituted or mono- or polysubstituted phenylmethoxyimino; unsubstituted or mono- or polysubstituted phenylhydroxymethyl; unsubstituted or mono- or polysubstituted 1-phenyl-1-hydroxyethyl; unsubstituted or mono- or polysubstituted phenylchloromethyl; unsubstituted or mono- or polysubstituted phenylcyanomethyl; unsubstituted or mono- or polysubstituted phenyl, in which the substituents in each case can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C<sub>1</sub>-C<sub>6</sub>alkyl, halo-C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, halo-C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkylthio, halo-C<sub>1</sub>-C<sub>6</sub>alkylthio, C<sub>1</sub>-C<sub>6</sub>alkylsulfinyl, halo-C<sub>1</sub>-C<sub>6</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl and halo-C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl; unsubstituted or mono- or polysubstituted phenoxy, in which the substituents can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C<sub>1</sub>-C<sub>6</sub>alkyl, halo-C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, halo-C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkylthio, halo-C<sub>1</sub>-C<sub>6</sub>alkylthio, C<sub>1</sub>-C<sub>6</sub>alkylsulfinyl, halo-C<sub>1</sub>-C<sub>6</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl and halo-C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl; unsubstituted or mono- or polysubstituted phenylacetylenyl, in which the substituents can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C<sub>1</sub>-C<sub>6</sub>alkyl, halo-C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, halo-C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkylthio, halo-C<sub>1</sub>-C<sub>6</sub>alkylthio, C<sub>1</sub>-C<sub>6</sub>alkylsulfinyl, halo-C<sub>1</sub>-C<sub>6</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl and halo-C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl; or unsubstituted or mono- or polysubstituted pyridyloxy, in which the substituents can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C<sub>1</sub>-C<sub>6</sub>alkyl, halo-C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, halo-C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkylthio, halo-C<sub>1</sub>-C<sub>6</sub>alkylthio, C<sub>1</sub>-C<sub>6</sub>alkylsulfinyl, halo-C<sub>1</sub>-C<sub>6</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl and halo-C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl;

or R<sub>7</sub> and R<sub>8</sub> are together C<sub>3</sub>-C<sub>5</sub>alkylene;

Ar is unsubstituted or mono- or polysubstituted phenyl, unsubstituted or mono- or polysubstituted hetaryl, unsubstituted or mono- or polysubstituted naphthyl or unsubstituted or mono- or polysubstituted quinolyl, in which in each case the substituents can be independent of one another and are chosen from the group consisting of R<sub>7</sub> and R<sub>8</sub>;

R<sub>9</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, halo-C<sub>1</sub>-C<sub>6</sub>alkyl, allyl, C<sub>1</sub>-C<sub>6</sub>alkoxymethyl or -C(O)R<sub>10</sub>;

R<sub>10</sub> is C<sub>1</sub>-C<sub>6</sub>alkyl, halo-C<sub>1</sub>-C<sub>6</sub>alkyl or C<sub>1</sub>-C<sub>6</sub>alkoxymethyl;

W is O, S, S(O<sub>2</sub>) or N(R<sub>11</sub>);

R<sub>11</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl;

a is 1, 2, 3 or 4;

b is 0, 1, 2, 3 or 4; and

n is 0, 1 or 2,

in which, if R<sub>7</sub> is hetaryloxy, the hetaryl group in R<sub>7</sub> is other than pyridyl; and

veterinary acceptable carriers and/or dispersants; whereby said veterinary pharmaceutical composition kill said parasites that live on or in said mammal when applied to said mammal.

Claims 9 -18. (Cancelled)

Claim 19. (Currently amended) A method of treating a mammal for parasites that live on or in said mammal comprising administering to said mammal in need of treatment thereof a parasitocidal effective amount of the veterinary pharmaceutical composition of Claim 8 wherein said veterinary pharmaceutical composition is well-tolerated by said mammal.

Claim 20. (Previously presented) The method of Claim 19 wherein said administration to said animal is topically, perorally, parenterally, or subcutaneously.

Claim 21. (Previously presented) The method of Claim 19 wherein said veterinary pharmaceutical composition of Claim 8 is in a formulation consisting of the group of pour-on, spot-on, tablet, chewie, powder, boli, capsules, suspension, emulsion, solution, injectable, water-additive, and food-additive.

Claim 22. (Previously presented) The method of Claim 19 wherein said parasites are endo-parasites.

Claim 23. (Previously presented) The method of Claim 19 wherein said parasites are helminthes.

Claim 24. (Previously presented) The method of Claim 22 wherein said endo-parasites are nematodes and trematodes.

Claim 25. (Currently amended) A method of controlling parasites that live on or in a mammal comprising administering to said mammal the veterinary pharmaceutical composition of Claim 8 wherein said veterinary pharmaceutical composition is well-tolerated by said mammal.

Claim 26. (Previously presented) The method of Claim 25 whereby said veterinary pharmaceutical composition is administered to said mammal topically, perorally, parenterally, or subcutaneously.

Claim 27. (Previously presented) The method of Claim 25 whereby said veterinary pharmaceutical composition is in a formulation consisting of the group of pour-on, spot-on,

tablet, chewie, powder, boli, capsules, suspension, emulsion, solution, injectable, water-additive, and food-additive.

Claim 28. (Previously presented) The method of Claim 25 wherein said parasites are endo-parasites.

Claim 29. (Previously presented) The method of Claim 28 wherein said endo-parasites are helminthes.

Claim 30. (Previously presented) The method of Claim 28 wherein said endo-parasites are nematodes and trematodes.

Claim 31. (Previously presented) The veterinary pharmaceutical composition of Claim 8 in which

R<sub>7</sub> is unsubstituted or mono- or polysubstituted C<sub>3</sub>-C<sub>6</sub>cycloalkoxy, unsubstituted or mono- or polysubstituted C<sub>3</sub>-C<sub>6</sub>cycloalkylthio or unsubstituted or mono- or polysubstituted (C<sub>3</sub>-C<sub>6</sub>cycloalkyl)(R<sub>9</sub>)N, in which the substituents in each case are chosen from the group consisting of halogen and C<sub>1</sub>-C<sub>6</sub>alkyl.

Claim 32. (Previously presented) The veterinary pharmaceutical composition of Claim 8 in which R<sub>1</sub> is hydrogen, C<sub>1</sub>-C<sub>4</sub>alkyl or halo-C<sub>1</sub>-C<sub>4</sub>alkyl;

R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> are, independently of one another, hydrogen, unsubstituted or mono- or polyhalogenated C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or mono- or polyhalogenated C<sub>2</sub>-C<sub>6</sub>alkenyl or unsubstituted or mono- or polyhalogenated C<sub>2</sub>-C<sub>6</sub>alkynyl;

R<sub>7</sub> is unsubstituted C<sub>3</sub>-C<sub>6</sub>cycloalkoxy, unsubstituted C<sub>3</sub>-C<sub>6</sub>cycloalkylthio or unsubstituted (C<sub>3</sub>-C<sub>6</sub>cycloalkyl)(R<sub>9</sub>)N;

R<sub>8</sub> is halogen, nitro, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl, halo-C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, halo-C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>2</sub>-C<sub>4</sub>alkenyl, halo-C<sub>2</sub>-C<sub>4</sub>alkenyl, C<sub>2</sub>-C<sub>4</sub>alkynyl, C<sub>3</sub>-C<sub>5</sub>cycloalkyl, C<sub>2</sub>-C<sub>4</sub>alkenyloxy, halo-C<sub>2</sub>-C<sub>4</sub>alkenyloxy, C<sub>1</sub>-C<sub>4</sub>alkylthio, halo-C<sub>1</sub>-C<sub>4</sub>alkylthio, C<sub>2</sub>-C<sub>4</sub>alkenylthio, halo-C<sub>2</sub>-C<sub>4</sub>alkenylthio, C<sub>1</sub>-C<sub>4</sub>alkylamino, di-C<sub>1</sub>-C<sub>4</sub>alkylamino, C<sub>1</sub>-C<sub>4</sub>alkylcarbonyl, halo-C<sub>1</sub>-C<sub>4</sub>alkylcarbonyl, C<sub>1</sub>-C<sub>4</sub>alkoxycarbonyl, unsubstituted or mono- or polysubstituted phenylamino, unsubstituted or mono- or polysubstituted phenylcarbonyl; unsubstituted or mono- or polysubstituted phenyl, in which the substituents in each case can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl, halo-C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, halo-C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>alkylthio and halo-C<sub>1</sub>-C<sub>4</sub>alkylthio; unsubstituted or mono- or polysubstituted phenoxy, in which the substituents can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl, halo-C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, halo-C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>alkylthio and halo-C<sub>1</sub>-C<sub>4</sub>alkylthio; or unsubstituted or mono- or polysubstituted pyridyloxy, in which the substituents can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl, halo-C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, halo-C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>alkylthio and halo-C<sub>1</sub>-C<sub>4</sub>alkylthio;

Ar is unsubstituted or mono- or polysubstituted phenyl or unsubstituted or mono- or polysubstituted hetaryl, in which in each case the substituents can be independent of one another and are chosen from the group consisting of R<sub>7</sub> and R<sub>8</sub>;

R<sub>9</sub> is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl or halo-C<sub>1</sub>-C<sub>6</sub>alkyl;

W is O, S or N(R<sub>11</sub>);

R<sub>11</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub>alkyl;

a is 1, 2 or 3;

b is 0, 1, 2 or 3; and

n is 0, 1 or 2.

Claim 33. (Previously presented) The veterinary pharmaceutical composition of Claim 8 in which R<sub>1</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub>alkyl;

R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> are, independently of one another, hydrogen or unsubstituted or mono- or polyhalogenated C<sub>1</sub>-C<sub>6</sub>alkyl;

R<sub>7</sub> is unsubstituted C<sub>3</sub>-C<sub>5</sub>cycloalkoxy or unsubstituted (C<sub>3</sub>-C<sub>5</sub>cycloalkyl)(R<sub>9</sub>)N;

R<sub>8</sub> is halogen, nitro, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl, halo-C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, halo-C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>3</sub>-C<sub>5</sub>cycloalkyl, C<sub>1</sub>-C<sub>4</sub>alkylcarbonyl, C<sub>1</sub>-C<sub>4</sub>alkoxycarbonyl, unsubstituted or mono- or polysubstituted phenyl, in which the substituents in each case can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl, halo-C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy and halo-C<sub>1</sub>-C<sub>4</sub>alkoxy; or unsubstituted or mono- or polysubstituted phenoxy, in which the substituents can be independent of one another and are chosen from the group consisting of halogen, nitro, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl, halo-C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, halo-C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>4</sub>alkylthio and halo-C<sub>1</sub>-C<sub>4</sub>alkylthio;

Ar is unsubstituted or mono- or polysubstituted phenyl, in which the substituents can be independent of one another and are chosen from R<sub>7</sub> and R<sub>8</sub>;

R<sub>9</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub>alkyl;

W is O or S;

a is 1 or 2;

b is 0 or 1; and

n is 1 or 2.

Claim 34. (Previously presented) The veterinary pharmaceutical composition of Claim 8 in which R<sub>1</sub> is hydrogen;

R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> are, independently of one another, hydrogen or unsubstituted C<sub>1</sub>-C<sub>4</sub>alkyl;

R<sub>7</sub> is unsubstituted C<sub>3</sub>-C<sub>4</sub>cycloalkoxy or unsubstituted (C<sub>3</sub>-C<sub>4</sub>cycloalkyl)(R<sub>9</sub>)N;

R<sub>8</sub> is halogen, nitro, cyano, C<sub>1</sub>-C<sub>2</sub>alkyl, halo-C<sub>1</sub>-C<sub>2</sub>alkyl, C<sub>1</sub>-C<sub>2</sub>alkoxy, halo-C<sub>1</sub>-C<sub>2</sub>alkoxy, C<sub>3</sub>-C<sub>4</sub>cycloalkyl, C<sub>1</sub>-C<sub>2</sub>alkylcarbonyl or C<sub>1</sub>-C<sub>2</sub>alkoxycarbonyl;

Ar is mono- or polysubstituted phenyl, in which the substituents can be independent of one another and are chosen from R<sub>8</sub>;

R<sub>9</sub> is hydrogen or C<sub>1</sub>-C<sub>2</sub>alkyl;

W is O;

R<sub>11</sub> is methyl;

a is 1;

b is 0; and

n is 2.

Claim 35. (Previously presented) The veterinary pharmaceutical composition of Claim 8, in which the at least one compound of formula (I) has the name N-[2-[2-cyano-1-[2-(cyclopropylmethylamino)-4,5-difluorophenoxy]propyl]-4-trifluoromethoxybenzamide.